INM
InMed Pharmaceuticals Inc.
Set alert
- YTD
- +50.94%
- 1 year
- -13.51%
- Open
- 1.55
- Prev close
- 1.63
- Mkt cap
- 8.79M
- Vol
- 36.68K
- Avg vol
- 70.15K
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.51
- High
- 1.61
- Forward P/E
- -0.75
- Beta
- 0.71
- Short ratio
- 0.12
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2025
- 50-d avg
- 4.94
- 200-d avg
- 5.37
- 1y target
- 0.00
Key statistics
- Market cap
- 3.36M
- Enterprise value
- 51.45M
- Trailing P/E
- 0.02
- Forward P/E
- -0.75
- PEG ratio
- 0.00
- Price / sales
- 0.73
- Price / book
- 4.53
- EPS (TTM)
- 230.40
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -166.94%
- Revenue (TTM)
- 4.60M
- Revenue growth
- -44.50%
- Free cash flow
- -4.02M
- Total cash
- 6.61M
- Total debt
- 962.66K
- Return on equity
- -72.08%
- Shares outstanding
- 718.08K
- Short % of float
- 0.87%
- 50-day average
- 4.94
- 200-day average
- 5.37
Analyst view
Consensus: none
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -54.20 | — | — |
| Sep 27, 2024 | Jun 1, 2024 | 0.00 | -3.80 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -3.60 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -3.80 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -15.20 | — | — |
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- inmedpharma.com
News
- InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
- InMed Pharmaceuticals Inc. (NASDAQ:INM) Shares Shorted: Short Interest Down 48.4% in September
- InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
- InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
- Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
- InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
- InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
Your note
Sign in to keep a note on INM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ERIC ASHLEY | Chief Executive Officer | Purchase | Feb 19, 2024 | 43,959 |
| HULL ANDREW HAROLD | Director | Purchase | Feb 20, 2024 | 38,258 |
| MANCINI ALEXANDRA DIANE JANET | Unknown | Sale | Jul 30, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 5.11% | 36,665 | 171.59K | Sep 29, 2024 |
| UBS Group AG | 1.48% | 10,602 | 49.62K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.39% | 2,833 | 13.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.35% | 2,515 | 11.77K | Sep 29, 2024 |
| HRT Financial LP | 0.27% | 1,918 | 8.98K | Sep 29, 2024 |
| Virtu Financial LLC | 0.20% | 1,421 | 6.65K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 5.80% | 41,665 | 194.99K | Oct 30, 2024 |